UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis
Phase 3
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2013-08-30
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT00139789
- Locations
- 🇺🇸
Schwarz, Milwaukee, Wisconsin, United States
A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety
Phase 3
Completed
- Conditions
- ANXIETY
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2013-08-30
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00139854
- Locations
- 🇺🇸
Schwarz, Milwaukee, Wisconsin, United States
A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease
Phase 3
Completed
- Conditions
- Parkinson's Disease
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00139867
- Locations
- 🇺🇸
Schwarz, Milwaukee, Wisconsin, United States
Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome
Phase 3
Completed
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 549
- Registration Number
- NCT00136045
- Locations
- 🇩🇪
Schwarz, Monheim, Germany
SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization
Phase 3
Completed
- Conditions
- Epilepsy
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 400
- Registration Number
- NCT00136019
Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome
Phase 3
Completed
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 811
- Registration Number
- NCT00135993
- Locations
- 🇺🇸
Schwarz, RTP, North Carolina, United States
Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy
Phase 3
Completed
- Conditions
- Diabetic Neuropathies
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 654
- Registration Number
- NCT00135109
- Locations
- 🇺🇸
Schwarz, RTP, North Carolina, United States
Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
Phase 2
Terminated
- Conditions
- Lupus Erythematosus, Systemic
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2012-04-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT00113971
- Locations
- 🇺🇸
Columbia Presbyterian Medical Center, New York, New York, United States
🇺🇸Lupus Center of Excellence, Pittsburgh, Pennsylvania, United States
🇺🇸Rheumatology Associates, Charleston, South Carolina, United States
Study of Epratuzumab in Systemic Lupus Erythematosus
Phase 3
Terminated
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2005-05-20
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 510
- Registration Number
- NCT00111306
A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 87
- Registration Number
- NCT00105040
© Copyright 2025. All Rights Reserved by MedPath